Biobased chemicals will inevitably be an important part of a sustainable organic chemical industry. Current efforts in biobased chemicals are largely driven by opportunistic chemical product targets requiring complete technology development from feedstock to final product for a specific molecule. To enhance the development of biobased chemicals, it is important to create strategies that can be more systematic and can leverage advancements across multiple final products. Discussed here is the concept of bioprivileged molecules, which are chemical intermediates that have the potential to be efficiently converted into a range of product molecules that can both directly replace existing petrochemicals and are novel molecules that impart enhanced performance properties in end-use applications. 
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Background
While chemicals derived from biomass have a long history, which actually predates petrochemicals, the growth of the organic chemical industry is intrinsically tied to technological development in the processing of fossil carbon (crude oil and natural gas). The heart of the petrochemical industry is the thermal cracking technology platform that gives rise to C2-C4 alkenes, benzene, toluene and xylenes (some of the aromatics are also recovered from other refinery streams). The molecules generated from the thermal cracking platform are subsequently converted to the broad array of chemicals that make up the prepondurance of the organic chemical industry. Although it was never called such at the time, the exploitation of thermal crackingderived molecules was essentially a highly successful application of the diversity-oriented synthesis (DOS) concept that has been proposed for small molecule drug discovery. 1 The forward synthesis used in DOS was required since petrochemical end-use applications were developed around the available molecules rather than a priori knowledge of what would be a useful chemical structure.
Against the background of the highly efficient and mature petrochemical enterprise, the desire to enhance the sustainability of the organic chemical industry has led to the start of the 21 st century having the most concerted effort in biobased chemical development. As is common with a "new" technology area, the rapidly expanding number of researchers working in biobased chemicals led to a plethora of creative approaches for synthesizing specific organic chemicals from a range of biomass feedstocks including carbohydrates, triglycerides, lignin, protiens, etc. A common feature of most of these efforts were opportunistic biomass feedstock transformations that could result in a biomass-derived chemical for directly replacing an established petrochemical, e.g., the same chemical product made from biomass rather than fossil carbon. The retrosynthesis of a target chemical product from a biomass feedstock has the sustainability logic of substituting renewable carbon for nonrenewable carbon. However, this opportunistic retrosynthesis of target chemical products used for developing biobased chemicals clearly stands in stark contrast to the genesis and maturation of the petrochemical industry.
The particularly pronounced differences are that the petrochemical industry is predicated on a platform feedstock conversion technology, thermal cracking, which is leveraged across a broad array of chemical products. concept of a synthetic biology foundry has been proposed by a number of groups with a nice summary recently presented. 6 The strength of this strategy is the systematic utilization of rapidly expanding tools to engineer biology for the synthesis of a desirable chemical through an increasingly rapid iterative design, build, test, learn (DBTL) cycle. The downside of the synthetic biology foundry is that unlike the original development of the organic chemical industry, it is instrinscally a retrosynthetic strategy.
A purely retrosynthetic strategy for the development of biobased chemicals requires that the target molecule is known. Clearly in the case of directly replacing petrochemicals, these chemical targets are already established. However, an important attraction of biobased chemicals is not only their potential for sustainable organic chemicals but also their potential for providing novel chemical compounds that can lead to improved performance in end-use applications. The connection to enduse application, i.e., polymers, specialty chemicals, preservatives, surfactants, etc., is vital since a novel compound has no inherent value without it. Working backwards from end-use properties to desirable chemical compounds necessitates understanding of structure-function relationships, e.g., knowing how a particular product property maps back to the chemical compound being used. In nearly all product development areas there has been significant effort directed towards developing structure-function relationships. While progress continues to be made due to increased computational capabilities, structure-function relationships that predict desirable novel chemical compounds remain elusive.
As an illustration of the challenge in developing structure-function relationships, the case of preservatives (personal care and household products) can be considered, since there is significant market interest in green preservatives that can replace alkyl parabens and benzoic acid. 7 The Green
Chemistry and Commercial Conference (GC3) in conjunction with their industrial members established a list of technical criteria a novel preservative must meet to be considered for commercialization, 8 which included:
a. activity for a broad spectrum including gram-negative and gram-positive bacteria, mold, yeast, In addition to these technical criteria, the preservative must also meet regulatory and health/safety criteria. Considering the technical criteria alone, it is difficult to imagine development of a robust structure-function relationship for preservatives that would allow for predicting a desirable novel chemical product for this application.
Bioprivileged Molecule Concept
There is no question that having structure-function predictive relationships would dramatically enhance the potential for finding valuable biobased chemicals. However, in the absence of having these robust relationships, biobased chemical synthesis strategies need to account for this issue.
We recently proposed such a strategy that utilizes bioprivileged molecules, which are defined as "biology-derived chemical intermediates that can be efficiently converted to a diversity of chemical products including both novel molecules and drop-in replacements." 9 As noted in that manuscript there are several important components to this definition:
1. It is an intermediate chemical species that can be generated from a biological feedstock, but cannot be effectively accessed from fossil carbon feedstocks. The idea of leverage from bioprivileged molecules can be demonstrated by considering the production of "sustainable" adipic acid. Given the significant environmental footprint of adipic acid production from petrochemical-derived cylcohexanol and cyclohexanone, adipic acid has received significant attention as a target molecule from biomass. Having a known target creates an opportunity to utilize a retrosynthetic strategy for developing an efficient reaction network for its production. Computational tools exist for finding such reaction networks in biological systems with one example being a program named Biological Network Integrated Computational Explorer (BNICE). 10, 11 This program utilizes an automated reaction network generation (NetGen) 12 approach to design synthethic pathways using reaction rules curated from biochemical reaction databases for identifying potential biological retrosynthetic pathways to a target molecule (see bottom of Figure 1 ). Once the possible biological pathways have been identified, the DBTL cycle can be utilized to develop an organism capable of synthesizing adipic acid. However, this approach would specifically develop a pathway for adipic acid only. Alternatively, the adoption of a bioprivileged molecule approach can be seen at the top of Figure 1 , in which the biological target is muconic acid rather than adipic acid. Integrating the biological production of muconic acid with simple hydrogenation would lead to adipic acid. 13 However, muconic acid has the desirable property that it can be leveraged as an intermediate to an array of chemical products with a few shown in the figure.
More expansivley, muconic acid can serve as a bioprivileged molecule. Previous work has shown that muconic acid can be chemically converted into a number of additional large-volume petrochemicals including caprolactam, caprolactone, hexamethylene diamine, and terephthalic acid. [14] [15] [16] However, muconic acid can also be converted to an array of novel molecules. We have recently shown that the NetGen computational approach can be used to explore DOS from a biological-derived intermediate molecule. 17 By incorporating 16 common catalytic reaction families; hydrogenation, hydrogenolysis, hydrodeoxygenation, hydrolysis, dehydration, hydration, decarbonylation, decarboxylation, ketonization, esterification, keto-enol tautomerization, ring-opening/closing, aldol condensation, Diels-Alder, ketone amination, epoxidation, and selective oxidation, potential product molecules acessible from the conversion of a bioprivileged molecule could be identified. Shown in Figure 2 is the forward reaction network that in principle is accessable from muconic acid through at most two reaction steps. As noted in the figure, there are both known molecules as defined as those listed in PubChem (shown in the boxes) as well as novel compounds (not boxed). While these are possible molecules from muconic acid, futher experimental work is needed to demonstrate the transformations. Importantly, the reaction network suggests molecules that could be explored if muconic acid was available as a bioprivileged molecule.
One such interesting novel molecule is 3-hexenedioic acid (HDA) which has recently been shown to be generated from the efficient partial hydrogenation of muconic acid. 18, 19 Introduction of HDA as a monomer in place of adipic acid allows for the synthesis of nylons containing an unsaturated C-C bonds in the polymer chain. These bonds can be subsequently chemically modified for introducing novel nylon properties. The product differentiation made possible by HDA creates an initial technological and economic impetus for the development of muconic acid. However, the potential to convert efficiently muconic acid into a broad number of direct replacement and novel molecules further enhances and leverages the desirable development of muconic acid by creating a virtuous technological and economic cycle extending beyond a single chemical product.
Importantly, the forward synthesis of HDA from muconic acid would not have been identified by simply targeting retrosynthesis of adipic acid.
Bioprivileged Molecule Development
We have previously discussed and shown "star" diagrams for other example bioprivileged molecules including triacetic acid lactone (TAL) and 5-hydroxymethylfurfural (HMF) that have received attention in the literature. 9 An additional emerging bioprivileged molecule is coumalic acid, which can be produced by the dimerization of biological-derived maleic acid. 20, 21 Potentially accessible products from coumalic acid have recently been presented as a computational case study. 17 While each of these chemical intermediates are demonstrations of bioprivileged molecules, the development of a bioprivileged molecule strategy can best be advanced if it can be utilized to create a more systematic approach for biobased chemical expansion.
It is instructive to consider how the example bioprivileged molecules were identified. In the cases of TAL and HMF, their known synthetic accessability from carbohydrates led to researchers using DOS to find useful known and novel chemical products that could be produced from them. For example, the novel chemical product 2,5-furandicarboxylic acid (FDCA) appears to be the first commercialization target utilizing HMF as the intermediate. FDCA was not a retrosynthetic target but was instead identified as forward synthesis product from HMF. In contrast, the original interest in muconic acid and coumalic acid was due to their potential use as precursors to terephthalic acid, which was seen as a promising and desirable chemical for a green replacement, coupled with knowledge that there were biosynthetic pathways for their synthesis. With that identification as the starting point, subsequent DOS led to determination of their value as bioprivileged molecules.
Given the success of those approaches in bioprivileged molecule identification, it is likely that other promising molecules could be found by adopting similar strategies. Unfortunately, the breadth of organic chemical options for either approach is daunting. In the former, biology synthesizes a vast number of metabolites, so it is difficult to imagine how to curate all of those molecules to those that are most promising. Targeting a final product is equally problematic given the large number of known organic chemical products.
Our first approach for creating a more systematic strategy for bioprivileged molecule development was to consider computational forward synthesis from C6 oxygenates using automated reaction network generation. 17 Constraining the candidate molecules to a preliminary list of just C6HxOy molecules created 29,252 possible molecules. Using down selection rules based on chemical features of known bioprivileged molecules, a set of 100 potential bioprivileged molecules were computationally determined. These 100 molecules need to be evaluated for the known and novel chemical products that can be efficiently synthesized with minimal subsequent transformaitons. In the case of novel chemical products, molecules that are similar in composition and structure to existing petrochemicals but with one additional functional group are particularly interesting. Also of interest, are bioprivileged molecules that can be used as a starting reactant for creating a library of compounds as was done in screening of a TAL-derived library for antimicrobial activity. 9 After curating the possible products from the bioprivileged molecule candidates, the potential of synthesizing the bioprivileged molecule can be considered.
While we are working on developing a systematic strategy for bioprivileged molecule identification, it remains an open question about how best to do so. Any such strategy would likely need to integrate computational capabilities for pathway design in biological systems, cheminformatics of chemical transformations and structure-function relationships in product applications. Given the complexity of performance parameters in end-use applications there will also envitability be a requirement for experimental screening of candidate molecules in product formulations. However, the utility of bioprivileged molecules makes the determination of such a strategy a worthwhile endeavor. 
